Patent Application US20260085058A1 for SOS1 Degraders Treating Cancers
Summary
The USPTO has published patent application US20260085058A1, which relates to compounds that degrade son of sevenless homolog 1 (SOS1) and their use in treating cancers, particularly KRAS-mutant cancers. The application was filed on August 11, 2023.
What changed
This document is a publication of a patent application (US20260085058A1) filed with the USPTO on August 11, 2023. The application discloses compounds designed to degrade the SOS1 protein, with a stated use in treating various cancers, specifically those with KRAS mutations. The inventors listed are Yu YUAN and Hao XIE.
As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on entities. However, it signals potential future developments in cancer therapeutics and may be of interest to pharmaceutical companies and researchers in the oncology space. The application is classified under CPC codes including C07D 401/14, A61K 31/517, A61P 35/00, and C07D 417/14.
Source document (simplified)
DEGRADERS OF SON OF SEVENLESS HOMOLOG 1
Application US20260085058A1 Kind: A1 Mar 26, 2026
Inventors
Yu YUAN, Hao XIE
Abstract
This disclosure relates to compounds which are degraders of son of sevenless homolog 1 (SOS1) and their use in treating cancers, in particular KRAS-mutant cancers.
CPC Classifications
C07D 401/14 A61K 31/517 A61P 35/00 C07D 417/14
Filing Date
2023-08-11
Application No.
19103367
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Organic Chemistry (C07D) publishes new changes.